Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Advisory Panel to Discuss Sanofi’s PCSK9 Inhibitor on May 27
May 16, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
- Abe Tells Key Govt Panel to Compile FY2016 Economic, Fiscal Blueprint by May-End
May 12, 2016
- National Cancer Center to Strengthen Systems for Genome-Based Personalized Medicine and Rare Cancers: Pres. Nakagama
May 12, 2016
- MHLW Orders Teijin Pharma to Review Documents Submitted for Reexamination of 6 Products Including Bonalon
May 12, 2016
- Pharmacists Can Make Big Contribution to Health Finances by Reducing Drug Waste: MHLW Study Group Chief
May 10, 2016
- 18 of 24 Drug Firms in Kumamoto Have No Production Problem after Quakes: MHLW Update
May 10, 2016
- Bisphosphonates under Review for Risk of Osteonecrosis of External Auditory Canal
May 9, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
- Chuikyo Member Prods MHLW to Present Data on Savings through Generic Use
April 28, 2016
- Govt Achieves 8 Numerical Targets for FY2015 Plan to Promote R&D in Healthcare Field
April 28, 2016
- Chuikyo OKs 7 Drugs Subject to Cost-Effective Review; Re-Pricing to Be Conducted in 2018
April 27, 2016
- Japan BCG Faces Business Improvement Order over Manufacturing Methods
April 27, 2016
- MHLW Panel Supports Ono’s Cancer Drug Carfilzomib
April 26, 2016
- 13 New Countries Join Japan-EU Mutual Acceptance Scheme for GMP Data
April 26, 2016
- PMDA Reviewing Risk of Hep B Virus Reactivation for Sovaldi, Harvoni, Other Hep C Drugs
April 26, 2016
- PMDA Now Has 560 Full-Time Employees in Review Division
April 25, 2016
- Making PMDA World’s Most Trusted Regulatory Authority through “Regulatory Innovation”: Chief Executive
April 25, 2016
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…